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Objective: Autologous vein is the conduit of choice for small artery reconstruction. Despite excellent patency, these
conduits undergo remodeling over time. The purpose of this study was to identify temporal gene expression in vein grafts
versus control veins through microarray analysis.
Method: Cephalic vein grafts (n  12) were used to bypass femoral arteries in canines. Vein grafts were harvested after 1,
7, 14, and 30 days. Normal contralateral cephalic vein served as control. Total RNA was isolated; its quantity and quality
were confirmed with spectrophotometry and gel electrophoresis. Affymetrix U133A GeneChips, comprising approxi-
mately 15,000 genes, were used to analyze differential gene expression at each time point. Statistical analysis was
performed with Affymetrix and dChip software to identify consistently upregulated and downregulated genes. Real-time,
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to
validate microarray data.
Results: Statistical analysis revealed that 49 genes were consistently upregulated and 31 genes were consistently
downregulated in all three animals at various time points. qRT-PCR to quantitatively assess messenger RNA expression
was performed on specific genes to validate the microarray data. Immunohistochemistry to qualitatively assess protein
expression was used for further validation. Hierarchical clustering with dChip identified additional genes with similar
temporal or functional expression patterns.
Conclusions: This is the first study to use microarray analysis with confirmatory qRT-PCR to identify altered genes after
vein bypass grafting. Oligonucleotide microarrays and hierarchical clustering are powerful tools to generate hypotheses
as the basis for additional research on gene expression in vein graft remodeling. Ultimately, identification of a temporal
sequence of differential gene expression may provide insights not preferred into the molecular mechanisms of vein graft
remodeling, but also into the pathways leading to intimal hyperplasia. (J Vasc Surg 2004;39:645-54.)
Autologous vein is the only conduit for small artery
reconstruction (5 mm), on the basis of short-term and
long-term patency results.1 Despite patency superior to
that with prosthetic conduits, vein grafts also undergo
changes that may lead to delayed failure.2,3 This failure
results from surgical trauma during vein harvesting and
subsequent exposure of the vein to new hemodynamic
forces in the arterial circulation.4,5 Vein grafts undergo
remodeling changes similar to intimal hyperplasia, that is,
vascular smooth muscle cell (VSMC) migration and prolif-
eration, with secondary extracellular matrix production.
This remodeling, or “arterialization,” causes vein grafts to
thicken with neointima, and can lead to recurrent stenosis
at any point along the conduit.
The mechanism of vein graft failure is unclear, but
altered gene regulation translates into altered anatomy.
Although various studies have identified individual genes
with altered expression in “arterialized” veins,6,7 there is
little understanding regarding temporal upregulation or
downregulation of these genes. Microarrays represent a
new technology to screen samples for thousands of genes at
once, compared with older methods that tediously look at
single genes and gene products, such as differential display
and Western blot analysis. Recent investigations identified
temporal genetic expression in animal models of prosthetic
arterial bypass grafting.8,9 A few in vitro studies used mi-
croarrays to examine shear-stressed Human Umbilical Vein
Endothelial Cells or mechanically induced VSMCs.10,11
However, this is the first in vivo study to evaluate differen-
tial gene expression in arterialized vein grafts by means of
oligonucleotide microarray analysis.
On the basis of vein graft failure patterns, the hypoth-
eses of this study were that vein bypass grafting causes
immediate gene alteration in the graft wall and anastomo-
ses; and that altered gene transcription into mRNA, and
translation into protein, are the initial events in vein graft
remodeling, and provide insights into molecular mecha-
nisms of vein graft intimal hyperplasia. Certain changes are
unavoidable on the basis of the inherent nature of surgical
removal and reimplantation of veins, but identification of
altered gene expression may provide new targets for inter-
vention.
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MATERIAL AND METHOD
Twelve canines (25 kg) were used for the study after
institutional review board approval. Care complied with the
Guide for the Care and Use of Laboratory Animals.
Procedure. The model was a unilateral reversed ce-
phalic vein to femoral artery interposition graft, as de-
scribed.12,13 On the basis of previous data for prosthetic
arterial grafting from this laboratory as well as related
studies from other laboratories, animals were designated
for vein graft harvesting at 1, 7, 14, or 30 days (n  3 at
each time point). With the animal under general anesthesia,
the left cephalic vein was lightly distended with saline
solution (containing heparin and papaverine) and placed
into culture media, as described.14 After heparinization
(100 U/kg), end-to-side anastomoses were created with
6-0 polypropylene (Prolene) sutures. The intervening right
femoral artery was transected, establishing a functional
end-to-end anastomosis. Protamine sulfate (0.3 mg/kg)
was given. This model mimics clinical protocols for distal
pedal and coronary artery reconstruction.
Harvesting was performed with the animal under gen-
eral anesthesia. At the same time as graft harvest, the right
cephalic vein was harvested and stored as described above,
to serve as control tissue for the vein graft from the same
animal. The vein graft was ligated immediately proximal to
both anastomoses to exclude sutures and arterial tissue.
The graft was flushed with saline solution; mid-portions of
vein graft and control vein were placed into formalin for
histologic analysis and immunohistochemistry. Remaining
portions were immediately placed into RNAlater (Qiagen,
Valencia, Calif) and stored at 20°C until RNA isolation.
All bypass grafts were patent at harvest.
RNA isolation. Samples were rotor-homogenized
and treated with proteinase K (Qiagen). Total RNA was
extracted with RNeasy Midi Kits (Qiagen). RNA quantity
was confirmed with spectrophotometry, and quality was
confirmed with Millennium Markers (Ambion, Austin,
Tex) on a denaturing agarose gel (Sigma, St Louis, Mo).
Although control veins yielded relatively less total RNA
than vein grafts did, absolute yields were sufficient for
microarrays and real-time, quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR). No pooling of
RNA from different samples was necessary.
Microarray analysis. Total RNA was prepared for
Affymetrix U133A GeneChips (Santa Clara, Calif) at our
Gene Array Technology Center. Complementary DNA was
synthesized from total RNA (GeneChip Sample Cleanup
Modules; Qiagen), a transcription reaction (Enzo BioArray
High Yield RNA Transcript Labeling Kit, Farmingdale,
NY) generated biotin-labeled cRNA. cRNA was frag-
mented and hybridized to the GeneChip. One batch of
GeneChips was used at 1 and 7 days, and another batch was
used at 14 and 30 days.
Affymetrix MAS 5.0 was used for statistical gene ex-
pression analysis to compare vein graft with control vein
from the same animal. A gene was upregulated in vein graft,
compared with control vein, if that gene was “PRESENT”
in vein graft (qualitative detection of a particular tran-
script); was “INCREASED” in vein graft (qualitative com-
parison of transcript signal using control array as baseline);
and had “SIGNAL LOG RATIO” of 1.0 or greater,
corresponding to “FOLD-CHANGE” of 2.0 or greater
(quantitative measure of relative change in transcript abun-
dance). A gene was downregulated if that gene was
“PRESENT” in control vein; was “DECREASED” in vein
graft; and had “SIGNAL LOG RATIO” of 1.0 or less,
corresponding to “FOLD-CHANGE” of 2.0 or less. To
ensure that genes were not discovered by random chance
within individual samples, genes had to satisfy the criteria in
all three animals at a time point.
dChip 1.2, a statistical program to analyze oligonucle-
otide microarrays,15 was also used to screen for differen-
tially expressed genes and to perform hierarchical clustering
of the samples.
qRT-PCR. qRT-PCR was performed with SYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
Calif).PrimerswerechosenusingPrimer3(availableat:http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.
cgi), validated with mFold (available at: http://
www.bioinfo.rpi.edu/applications/mfold/old/dna/
form1.cgi), and obtained from Integrated DNA
Technologies (Coralville, Ia):
18S (mammalian): 5-CGGCTACCACATCCAAGGAA-3
and 5-GCTGGAATTACCGCGGCT-3
HIF-1 (dog): 5-GCTGCTGGAGACACAATCAT-3
and 5-TCGAAGTGGCTTTGGAGTT-3
VEGF (dog): 5-ACCTCCACCATGCCAAGT-3 and
5-GGTACTCCTGGAAGATGTC-3
Smoothelin (perfect homology between mouse and human
being): 5-AAGGCCATGATTGAGAAGCT-3 and
5-GAGGAGAAGTTCTGGATGTC-3
RNA was compared between vein graft and control vein
from the same animal; samples were simultaneously ana-
lyzed for 18S RNA as standardization. Reaction triplicates
included 12.5 L SYBR Green Master Mix, 1.25 L prim-
ers (5 mol/L each of forward and reverse primers),
10.125 L of nuclease-free water, 1 L of RNA (1 g/
mL), and 0.125 L of MMLV-RT. Experiments included
negative reverse transcription controls and negative tem-
plate controls to monitor contamination. The ABI PRISM
7700 Sequence Detection System conditions were as fol-
lows: stage 1 (reverse transcription), 30 minutes (48°C);
stage 2 (reverse transcriptase inactivation), 10 minutes
(95°C); stage 3 (denaturation, then annealing/extension),
15 seconds (95°C) and 1 minute (60°C), for 40 cycles.
Histologic analysis and immunohistochemis-
try. Mid-portions of each vein graft and control vein were
processed through ethanol and embedded in paraffin. Six-
micrometersectionswerecut,andstainedwithhematoxylin-
eosin. For immunohistochemistry, 6-m sections were
deparaffinized in xylene, and rehydrated. Heated citrate
buffer antigen retrieval was performed when necessary.
Sections were treated with 3% hydrogen peroxide. Non-
serum protein blocking was followed by incubation over-
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night with primary antibody. Sections were incubated with
biotinylated secondary antibody, streptavidin-peroxidase,
and DAB (3,3-diaminobenzidine)–chromagen, then
counterstained with hematoxylin. Positive and negative
controls were used.
The antibodies and dilutions used were -smooth mus-
cle actin (1:25; DAKO, Carpinteria, Calif), Ki-67 (1:150;
DAKO), VEGF (1:400; Santa Cruz Biotechnology, Santa
Cruz, Calif), and HIF-1 (1:150; Santa Cruz Biotechnol-
ogy). The kits used were DAKO LSAB Kit, peroxidase,
and DAKO Animal Research Kit, peroxidase.
RESULTS
Microarray analysis. Microarray data are available at
http:// home. caregroup. org/ templatesnew/ departments/
BID/vonliebig/uploaded_documents/kalishveinbypassdata.
htm. Affymetrix U133A GeneChips probe for approxi-
mately 15,000 known genes (22,283 probe sets). Samples
achieved 18% to 26% hybridization with GeneChips (mean,
22.9%  2.4%  3435  360 genes [5102  535 probe
sets]). On the basis of statistical standards endorsed in
bioinformatics research, comparisons were made between
vein graft and control vein from the same animal. At all four
time points combined (with consistent upregulation or
downregulation required in all three animals at a given time
point), 49 genes were upregulated and 31 genes were
downregulated (Tables I, II). Numbers reflect average
gene fold changes in vein graft compared with control vein
in all three animals. Consistent upregulation or downregu-
lation of a gene in three animals facilitated statistical
significance.
dChip 1.2 was used to analyze GeneChip output and
compare gene expression at each time point. Hierarchical
clustering revealed that control veins clustered together
and vein grafts clustered together within each GeneChip
batch (Fig 1). Individual time points subclustered, with the
exception of vein graft sample 07h1, owing to 8% outliers.
The clustering algorithm is as follows: distance between
two genes is defined as 1  r, where r is the correlation
coefficient between the standardized expression values of
two genes. Two closest genes are merged into a supergene
and connected by branches, with length representing dis-
tance. The expression value of this supergene is the average
of standardized expression values of the two genes (cen-
troid linkage). The next pair of genes (supergene) with the
smallest distance is merged, and the process is repeated to
merge all genes.15
qRT-PCR. To validate microarray data, qRT-PCR
was performed to assess RNA expression level accuracy.
Mathematically normalizing HIF-1 results at 1 day with
the standardization gene 18S revealed 2.5-fold upregula-
tion of HIF-1 in vein graft versus control vein (Fig 2, A
and B), confirming the microarray data. At 7 days HIF-1
had returned to baseline levels when normalized to 18S
(Fig 2, C and D). Similar results were obtained at 14 and 30
days (graphs not shown). Confirmatory qRT-PCR was
similarly performed for VEGF and Smoothelin; results at
each time point correlated with microarray data (graphs not
shown).
Histologic analysis. Because vein grafts can fail at any
place along the conduit, sections were taken from the
mid-portion, where minimal trauma from manipulation
would have occurred. Anastomoses were excluded because
of this increased trauma inherent in the operation. It was
believed that certain anastomotic genes might be absent
from the remaining bypass graft but that all genes from
minimally traumatized areas would be present at anastomo-
ses. Control vein had an intact endothelial cell layer before
implantation (Fig 3, A). After 1 day there were migrating
neutrophils and a dense layer of endothelial cells or
VSMCs. After 7 days (Fig 3, B) there was a distinct layer of
luminal intimal hyperplasia. After 14 days (Fig 3, C) there
was medial hypertrophy and a layer of intimal hyperplasia.
After 30 days (Fig 3, D) there was increased medial hyper-
trophy accompanied by extracellular matrix deposition.
Immunohistochemistry. Because of its relation to
HIF-1, the other index gene used to validate the microar-
ray was VEGF. VEGF antibody qualitatively demonstrated
increased protein expression in vein grafts at day 1 com-
pared with vein grafts at 7, 14, and 30 days (Fig 4, A-C;
14-day data not shown). Human placenta served as positive
control, and appropriate negative controls were used. Ki-67
was used early, at 1 and 7 days, to identify cell proliferation
(Fig 4, D and E). -Smooth muscle actin identified VSMCs
(Fig 4, F-H).
DISCUSSION
Vein bypass grafting causes remodeling changes sim-
ilar to those of intimal hyperplasia.5 Early changes initi-
ate a sequence of genetic events in the vein graft wall and
anastomoses; however, this genetic cascade has not been
elucidated. This is the first study to use microarray
analysis to identify a time line of genetic expression in an
in vivo model of vein bypass grafting and to validate
microarray results with qRT-PCR and immunohisto-
chemistry. This study analyzed paired specimens from
the same animal. Three animals were used at each time
point, and four time points comprised the time line.
Tables I and II suggest gene variability over time, fulfill-
ing a major goal of the study. Analysis revealed 49
upregulated genes and 31 downregulated genes at the
various time points.
HIF-1 and VEGF were upregulated in vein grafts
after 1 day, and returned to baseline levels thereafter. These
genes were chosen as the index genes to validate microar-
ray results, because they have been studied extensively in
intimal hyperplasia. When a vein is used as an arterial
conduit, physiologic and morphologic changes occur,
including endothelial cell loss and recovery, wall thick-
ening, and development of a variable layer of neointima.6
When a vein is removed from its natural position and
grafted, it suffers hypoxic stress. Hypoxia induces VEGF
expression in both endothelial cells and VSMCs.16,17
This hypoxia most likely accounts for upregulation of
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HIF-1 and VEGF at 1 day. Exogenous VEGF increases
reendothelialization after balloon catheter denudation
injury.18 Thus it is possible that VEGF is induced early,
when the endothelial cells are partially lost, to promote
reendothelialization. Similarly, VEGF may have returned
to baseline by 7 days, either because endothelial cells
have repopulated or simply because normoxic conditions
have been restored.
Intimal hyperplasia leads to production of extracellular
matrix, which incorporates collagens.19 In this study cer-
tain collagens were downregulated at 1 day and subse-
quently became upregulated, including collagen type I
(2) and procollagen-1 (type III). Variably upregulated
collagens included collagen types I, III, IV, and XI, and
procollagen type I. Collagens were also discovered by
Geary et al9 at 30 days. These data support sequential gene
Table I. Upregulated genes from microarray analysis
Accession no. Gene description
Average fold changes*
1 Day 7 Day 14 Day 30 Day
NM_000089.1 Collagen. type I,  2 3.9 7.9 2.6 2.6
AU144167 Procollagen  1 (type III) chain precursor 3.8 9.5 3.0 2.8
K01228.1 Proalpha (I) chain of type I procollagen 16.0 10.4 9.9
NM_000090.1 Collagen, type III  1 7.5 4.5 3.7
D21254.1 OB-cadherin-1 4.1 3.9 2.0
NM_001827.1 CDC28 protein kinase 2 (CKS2) 8.9 3.1
NM_016594.1 FK506 binding protein precursor 7.3 3.4
NM_002356.4 MARCKS (80K-L) 4.6 3.2
J04177  1 type XI collagen (COL11A1) 23.2 11.7
L37882.1 Frizzled gene product 11.6 9.3
A1743621 Collagen. type I  1 7.8 4.5
A J297586.1 MHC class II antigen (HLA-DRB1 gene) 5.3 3.7
NM_004385.1 Chondroitin sulfate proteoglycan 2 (Versican) 3.1 2.9
M10943 Metallothionein-If gene (hMT-If) 19.8
NM_005953.1 Metallothionein 2A (MT2A) 15.7
NM_025195.1 Phosphoprotein regulated by mitogenic pathways 9.6
NM_005952.1 Metallothionein 1X (MT1X) 9.2
AK000168.1 CD24 signal transducer 7.7
AF216292.1 Endoplas retic lumenal Ca2 binding protein grp78 5.5
BE971383 Spermidinespermine N1-acetyltransferase 5.3
AL564683 CCAAT enhancer binding protein (CEBP) beta 5.1
NM_005951.1 Metallothionein 1H (MT1H) 4.2
NM_002450.1 Metallothionein 1L (MT1L) 4.1
NM_003254.1 Tissue inhibitor of metalloproteinase 1 (TIMP1) 4.0
AF022375.1 Vascular endothelial growth factor (VEGF) 3.7
AF333388.1 Metallothionein 1H-like protein 3.5
NM_006644.1 Heat shock 105kD (HSP105B) 3.3
AA761181 CD24 antigen 3.1
NM_003878.1 	-glutamyl hydrolase (GGH) 3.1
NM_002032.1 Ferritin. heavy polypeptide 1 (FTH1) 2.8
NM_001530.1 Hypoxia-inducible factor 1.  subunit (HIF-1) 2.7
NM_014302.1 Sec61 	 (SEC61G) 6.5
BF718636 H2A histone family, member Z 4.1
NM_030938.1 Hypothetical protein DKFZp5661133 3.9
BG034239 Rho guanine nucleotide exchange factor (GEF) 3.3
NM_021103.1 Thymosin, 
 10 (TMSB10) 2.7
NM_002106.1 H2A histone family, member Z (H2AFZ) 2.6
BC000905.1 RAB1, member RAS oncogene family 2.1
D32039.1 Proteoglycan PG.M(V3) 9.1
NM_003746.1 Dynein, cytoplasmic, light polypeptide (PIN) 5.3
NM_004887.1 Small inducible cytokine subfamily B 4.3
NM_004161.1 RAB1, member RAS oncogene family (RAB1) 4.1
NM_001747.1 Capping protein (actin filament), gelsolin-like 4.1
NM_001845.1 Collagen, type IV  1 (COL4A1) 3.4
BE465032 Hypothetical protein FLJ12619 3.1
AL136179 SOX4 gene for SRY 2.5
AF217963.1 NRAGE 2.5
AL537042 ADP-ribosylation factor 4 2.4
NM_006854.2 KDEL endoplas retic protein retention receptor 2 2.3
*Average fold changes are listed from the three animals at each time point.
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regulation dictated by changes in the adaptive and healing
responses of the vein graft wall.
In addition to collagens, seven additional genes were
upregulated at more than one time point. Myristoylated
alanine-rich protein kinase C substrate is the most promi-
nent cellular substrate for protein kinase C. The protein
binds calmodulin, actin, and synapsin, and also helps regu-
late endothelial cell proliferation.20 Cyclin-dependent ki-
nase regulatory subunit (CDC28) coordinates regulation
of cellular proliferation and migration.21 Versican connects
cells with extracellular matrix, in addition to its regulatory
role during cell migration and proliferation.22
Seven additional genes were downregulated at more
than one time point. Smoothelin is a marker of mature,
contractile VSMCs.23 Zinc finger proteins are transcription
factors for other genes, including non-muscle myosin heavy
chain B, which is a marker of phenotypically modulated
smooth muscle cells.24 RNA binding protein gene modu-
lates the biologic processes of RNA processing, transport,
and translation.25
The analysis performed with dChip facilitated hierar-
chical clustering of the data. The principle of hierarchical
clustering is that coregulated genes with similar patterns of
expression are more likely to be involved in the same
biologic pathway. Before drawing conclusions, however,
each related gene requires the same stringent validation as
used in this study. As noted, one GeneChip batch was used
at days 1 and 7, and a different batch was used at 14 and 30
days. The ensuing “batch effect” gives the appearance of
altered gene expression in control veins, but the altered
expression similarly extends to the vein grafts and thus does
not influence comparative results. The two main batches
form two main sample clusters (Fig 1). Within the main
sample clusters, vein grafts clustered together and control
veins clustered together. The subclustering of individual
time points within each batch emphasized the reproducibil-
ity of this experiment. Overall, the importance of hierarchi-
cal clustering was to enable visualization of sample cluster-
ing and to generate hypotheses to guide future research
into pathways of related genes.
A potential critique of this work is against creating a
time line of genetic expression for vein graft intimal hyper-
plasia on the basis of three animals at each of four time
points. However, the model is justified, given the strict
criteria to judge gene “significance,” as well as repetition
within three biologically different samples. Statistical stan-
dards for claiming significance (fold-changes 2.0 or
2.0) were adopted from other bioinformatics studies.11,26
Table II. Downregulated genes from microarray analysis
Accession no. Gene description
Average fold changes*
1 Day 7 Day 14 Day 30 Day
S67238.1 Smooth muscle myosin heavy chain isoform SM2 5.5 4.7 2.1
NM_006006.1 Zinc finger protein 145 (ZNF-145) 3.5 3.2 3.1
U16153.1 Id-4H protein 5.7 3.0
AF064238.3 Smoothelin large isoform L2 (SMTN) 5.5 5.3
D84109.1 RBP-MS type 3 5.0 6.2
NM_002480.1 Myosin phosphatase, target subunit 1 (MYPT1) 3.1 2.2
D49958.1 Membrane glycoprotein M6 2.9 2.8
AF138302.1 Decorin variant C 7.4
AI978623 KIAA0657 protein 7.0
NM_000366.1 Tropomyosin 1 () (TPM1) 6.0
AF138300.1 Decorin variant A 6.0
AI949687 Transcription factor 7–like 2 5.1
AF138303.1 Decorin D 3.9
AW157094 Inhibitor of DNA binding 4 3.9
AI625550 Filamin A,  (actin-binding protein-280) 3.8
AL037401 Nuclear receptor subfamily 2, group F, member 2 3.6
BC001283.1 Nuclear factor IB 3.5
NM_015642.1 Zinc finger protein 288 (ZNF288) 3.5
AW149417 OLF-1EBF associated zinc finger gene 3.2
NM_002961.2 S100 calcium-binding protein A4 (S100A4) 2.9
AA045174 DKFZp586B211 2.9
BE734356 Myosin, light polypeptide 6, alkali, smooth muscle 2.7
AI700518 Nuclear factor IB 2.7
NM_001615.2 Actin, 	 2, smooth muscle, enteric (ACTG2) 2.5
NM_006867.1 RNA-binding protein gene with multiple splicing 2.4
AL523076 3UTR of unknown protein 2.4
AW084582 Splicing factor, arginine serine–rich 5 2.3
AI591100 Neuroendocrine secretory protein 55 2.2
U69546.1 RNA-binding protein BRUNOL3 3.5
BF697964 Destrin (actin depolymerizing factor) 2.7
AL535113 Phospholipase C, 
 4 3.2
*Average fold changes are listed from the three animals at each time point.
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Numerous studies with Affymetrix GeneChips re-
vealed less than 2% rates of gene discovery due to array
noise or chance,27 and performing biologic replicates
decreases this rate.28 Even if there is a 5% chance of a
gene being significantly regulated in one dog (higher
than the accepted rate of 2%), the chance that it is
significant in three dogs is 5%  5%  5%  0.0125%.
Therefore, from approximately 15,000 genes (22,283
probe sets) this would still equal only 1.88 genes (2.78
probe sets) due to noise or chance, representing a false
discovery rate of 3.8% of the 49 upregulated genes and
6.0% of the 31 downregulated genes. False discovery rate
calculated with dChip averaged 1.58% (1.4%, 3.0%,
0.6%, and 1.3% at each time point). The false discovery
rate was determined with statistical analysis of 50 permu-
tations of control and experimental data at each time
point. These statistical algorithms lend power to the
contention that nearly all 49 upregulated genes and
Fig 1. dChip hierarchical clustering diagram shows sample clustering. Each row corresponds to a single gene; each
column corresponds to a single sample. Columns to the left of midline are one batch of arrays (days 1 and 7); columns
to the right are the other batch (days 14 and 30). Blue, Degrees of downregulation; red, degrees of upregulation; H,
hyperplasia samples (vein grafts); C, control samples (control veins).
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nearly all 31 downregulated genes are not due to array
noise or chance.
A debate in microarray papers regards cDNA versus
oligonucleotide arrays. The U133A GeneChip, an oligonu-
cleotide microarray, contains the most current and compre-
hensive list of genes to date. It uses multiple probe sets for
each gene, including perfect matches and a mismatch probe
set, to increase the statistical certainty that a gene deemed
significant is not an error due to chance. Overall, as es-
poused by Li et al29 from studying neuroblastoma cell lines,
oligonucleotide arrays are more reliable for evaluating gene
expression than cDNA arrays.
Geary et al9 examined 30-day gene expression in mon-
key models of prosthetic arterial grafting to profile VSMC
populations. The media from native aorta and vena cava,
and neointima stripped from expandable polytetrafluoro-
ethylene grafts were placed onto cDNA arrays to generate
lists of regulated genes. Hilker et al30 used cDNA arrays,
but with only 91 genes, to examine aortocoronary bypass
graft stenosis. Failed grafts (mean, 94.1 months) were
compared with saphenous veins used for repeat grafts; six
genes achieved twofold upregulation in at least three of five
samples from human beings. Although many of the genes
of Geary et al and Hilker et al are similar to those discovered
Fig 3. Hematoxylin-eosin staining. A, Control vein (400). B,
At 7 days vein graft shows intimal hyperplasia (100). C, At 14
days vein graft shows medial hypertrophy and intimal hyperplasia
(100). D, At 30 days vein graft shows medial hypertrophy and
extracellular matrix deposition (100). L, Lumen.
Fig 2. Graphs show quantitative real-time reverse transcriptase polymerase chain reaction. A, One-day vein graft (blue)
shows 0.75 times the expression of HIF-1 as control vein (red). B, One-day vein graft (blue) shows 0.30 times the
expression of 18S as control vein (red). Normalizing HIF-1 results by 18S reveal 2.5-fold upregulation of HIF-1 in
vein graft vs control vein, confirming the microarray data. C, Seven-day vein graft (blue) shows 0.22 times the
expression of HIF-1 as control vein (red). D, Seven-day vein graft (blue) shows 0.25 times the expression of 18S as
control vein (red). Normalization reveals return of HIF-1 to baseline levels in vein graft vs control vein.
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here, our vein graft model seeks to answer different ques-
tions than prosthetic grafting or failed vein grafts, and
further analysis is necessary before drawing conclusions
about similar genes.
Nevertheless, Geary et al9 and others8,31 prove that
human array technology can be used to adequately study
gene expression in various species. The canine model of
vascular grafting has long been established as the model
most similar to human beings with regard to failure pattern
and healing mode.32 Although canine arrays are not cur-
rently available, genes are conserved across species, and the
number of known canine genes homologous to the human
genome increases as the canine genome is mapped.33 Ca-
nine tissue on human arrays is justified with independent
validation of genes, as with qRT-PCR or immunohisto-
chemistry. Although decreased hybridization of canine tis-
sue to human arrays probably caused omission of some
important genes, those genes that were discovered still pro-
vide an important foundation for vein graft intimal hyperplasia
genetics.
Despite this overall justification, certain genes previ-
ously associated with models of intimal hyperplasia are
noticeably absent from the microarray data. These include
basic fibroblast growth factor, angiotensinogen, platelet-
derived growth factor A, transforming growth factor-
,
osteopontin, and elastin. Whether these differences are due
to species variability or statistical selection criteria will need
to be investigated. In addition, genes associated with vein
graft remodeling are presumably not identical to genes
expressed after injury models and prosthetic arterial graft-
ing.
Although alternative models exist to study vein bypass
grafting, none mimics human clinical procedures as well as
this canine model. Mouse and rat models do not represent
the natural progression of vein graft intimal hyperplasia,
because these wire and balloon injury models more closely
resemble clinical procedures of angioplasty or stenting.
Monkeys are an option, but similar problems arise with
non-human tissue on human arrays. Even human tissue
placed on human arrays suffers hybridization ineffi-
Fig 4. Immunohistochemical staining to qualitatively localize protein expression of VEGF (A-C), Ki-67 (D, E), and
actin (F-H) at 1, 7, and 30 days (X 100). L,  Lumen.
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ciency, with rates in the literature ranging between 30%
and 40%.
To gain more insight into gene localization, laser cap-
ture microdissection (LCM) may be used in future studies.
LCM is a new tool for studying gene expression, and
expands on current localization methods of immunohisto-
chemistry or in situ hybridization. The technique enables
microscopic visualization and isolation of selected cell pop-
ulations from tissue sections. With LCM, areas of vein wall
media can be isolated and compared with isolated areas of
neointima, and RNA can be extracted from individual cell
populations for qRT-PCR.
In conclusion, microarray analysis is not an end in
and of itself, but serves as a platform to generate and test
multiple hypotheses. The power of microarray technol-
ogy and hierarchical clustering is the ability to facilitate
simultaneous assessment of the constellations of genetic
expression and to help identify patterns that might oth-
erwise not have been discovered through searches of
individual genes. To our knowledge, this is the first study
to use microarray analysis to identify upregulated or
downregulated genes after vein bypass grafting and to
validate the microarray results with qRT-PCR and im-
munohistochemistry. Creation of a time line of differen-
tial gene expression for vein graft remodeling can pro-
vide new insights into the mechanisms of neointima
formation, and may ultimately reveal targets for thera-
peutic intervention.
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